9183 related articles for article (PubMed ID: 17469741)
1. Results of the determination of serum markers in patients with malignant melanoma.
Lugović L; Situm M; Buljan M; Poduje S; Sebetić K
Coll Antropol; 2007 Jan; 31 Suppl 1():7-11. PubMed ID: 17469741
[TBL] [Abstract][Full Text] [Related]
2. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients.
Garbe C; Leiter U; Ellwanger U; Blaheta HJ; Meier F; Rassner G; Schittek B
Cancer; 2003 Apr; 97(7):1737-45. PubMed ID: 12655531
[TBL] [Abstract][Full Text] [Related]
4. Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients.
Schmitz C; Brenner W; Henze E; Christophers E; Hauschild A
Anticancer Res; 2000; 20(6D):5059-63. PubMed ID: 11326668
[TBL] [Abstract][Full Text] [Related]
5. [Laboratory markers of melanoma progression].
Bánfalvi T; Edesné MB; Gergye M; Udvarhelyi N; Orosz Z; Gilde K; Kremmer T; Ottó S; Tímár J
Magy Onkol; 2003; 47(1):89-104. PubMed ID: 12704461
[TBL] [Abstract][Full Text] [Related]
6. [S-100B and MIA (melanoma inhibiting activity) serum proteins: a prospective study of their value as melanoma progression markers].
Dornier C; Dousset B; Legras B; Barbaud A; Schmutz JL
Ann Dermatol Venereol; 2002 May; 129(5 Pt 1):739-40. PubMed ID: 12124520
[No Abstract] [Full Text] [Related]
7. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma.
Bosserhoff AK; Kaufmann M; Kaluza B; Bartke I; Zirngibl H; Hein R; Stolz W; Buettner R
Cancer Res; 1997 Aug; 57(15):3149-53. PubMed ID: 9242442
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma.
Hofmann MA; Gussmann F; Fritsche A; Biesold S; Schicke B; Küchler I; Voit C; Trefzer U
Melanoma Res; 2009 Feb; 19(1):17-23. PubMed ID: 19104451
[TBL] [Abstract][Full Text] [Related]
9. Serum markers in skin melanoma--preliminary study.
Dumitraşcu G; Constantin C; Manda G; Hristescu S; Mărgaritescu I; Chiriţă D; Neagu M
Roum Arch Microbiol Immunol; 2009; 68(3):125-35. PubMed ID: 20361532
[TBL] [Abstract][Full Text] [Related]
10. MIA, a novel serum marker for progression of malignant melanoma.
Bosserhoff AK; Lederer M; Kaufmann M; Hein R; Stolz W; Apfel R; Bogdahn U; Buettner R
Anticancer Res; 1999; 19(4A):2691-3. PubMed ID: 10470221
[TBL] [Abstract][Full Text] [Related]
11. Clinical value of combined determination of plasma L-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma.
Garnier JP; Letellier S; Cassinat B; Lebbé C; Kerob D; Baccard M; Morel P; Basset-Seguin N; Dubertret L; Bousquet B; Stoitchkov K; Le Bricon T
Eur J Cancer; 2007 Mar; 43(4):816-21. PubMed ID: 17276671
[TBL] [Abstract][Full Text] [Related]
12. S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase.
Krähn G; Kaskel P; Sander S; Waizenhöfer PJ; Wortmann S; Leiter U; Peter RU
Anticancer Res; 2001; 21(2B):1311-6. PubMed ID: 11396205
[TBL] [Abstract][Full Text] [Related]
13. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance and diagnostic value of protein S-100 and tyrosinase in patients with malignant melanoma.
Andrés R; Mayordomo JI; Visus C; Isla D; Godino J; Escudero P; Saenz A; Ortega E; Lastra R; Lambea J; Aguirre E; Elosegui L; Marcos I; Ruiz-Echarri M; Millastre E; Sáez-Gutierrez B; Asin L; Vidal MJ; Ferrer A; Giner A; Larrad L; Carapeto FJ; Tres A
Am J Clin Oncol; 2008 Aug; 31(4):335-9. PubMed ID: 18845991
[TBL] [Abstract][Full Text] [Related]
15. Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients.
Sanmamed MF; Fernández-Landázuri S; Rodríguez C; Lozano MD; Echeveste JI; Pérez Gracia JL; Alegre E; Carranza O; Zubiri L; Martín-Algarra S; González A
Clin Chim Acta; 2014 Feb; 429():168-74. PubMed ID: 24333389
[TBL] [Abstract][Full Text] [Related]
16. [Serum levels of S-100b protein after four years follow-up of patients with melanoma].
Zissimopoulos A; Karpouzis A; Karaitianos I; Baziotis N; Tselios I; Koutis C
Hell J Nucl Med; 2006; 9(3):204-7. PubMed ID: 17160167
[TBL] [Abstract][Full Text] [Related]
17. Prognostic role of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction for tyrosinase mRNA in patients with melanoma.
Visús C; Andres R; Mayordomo JI; Martinez-Lorenzo MJ; Murillo L; Sáez-Gutiérrez B; Diestre C; Marcos I; Astier P; Godino J; Carapeto-Marquez de Prado FJ; Larrad L; Tres A
Melanoma Res; 2007 Apr; 17(2):83-9. PubMed ID: 17496783
[TBL] [Abstract][Full Text] [Related]
18. Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling.
Findeisen P; Zapatka M; Peccerella T; Matzk H; Neumaier M; Schadendorf D; Ugurel S
J Clin Oncol; 2009 May; 27(13):2199-208. PubMed ID: 19307507
[TBL] [Abstract][Full Text] [Related]
19. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma.
Deichmann M; Benner A; Bock M; Jäckel A; Uhl K; Waldmann V; Näher H
J Clin Oncol; 1999 Jun; 17(6):1891-6. PubMed ID: 10561230
[TBL] [Abstract][Full Text] [Related]
20. Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma.
Abraha HD; Fuller LC; Du Vivier AW; Higgins EM; Sherwood RA
Br J Dermatol; 1997 Sep; 137(3):381-5. PubMed ID: 9349333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]